What changed
$RVMD — AVOID 📊 | 6 MONTHS THESIS
🎯 Q2 2026 | EPS $-1.90 vs $-1.90 ➖
💡 Consensus expects rapid pipeline success, but the EPS miss signals higher cash burn and potential dilution, while trial setbacks remain probable given early-stage oncology risk.
📉 Reward/risk: 1.2:1
🏢 Business Quality: 7/10 - innovative RAS platform with strong science, but early clinical stage and unproven commercialization.
📊 Valuation: rich - P/S 290x, EV/Sales ~285x, far above large-cap biotech peers; reverse DCF implies $10B+ revenue in 5 years, which is improbable.
🔮 Catalyst: No clear near-term catalyst post-earnings; next potential data readout likely Q4 2026 or later.
💰 Entry: $182.08, stop $-51.33, target $-88.4
⚖️ Avoid RVMD shares at $160 on a 3-month horizon due to extreme valuation and unattractive risk/reward following EPS miss.
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/RVMD0617